Our management team and board of directors provide the foundation on which the company is built. We have assembled a world-class team with proven experience in oncology drug development, from discovery to approval. We are well equipped to execute our clinical development plan and versatile enough to take advantage of other exciting opportunities along the way.
Daniel Gold, PhD
President & Chief Executive Officer
Dan took the helm in April 2010. Under his leadership, the company has established its headquarters in the U.S., assembled a proven oncology drug development team, developed a pipeline of clinical-stage assets and established a strong financial position.
Robert Mass, MD
Chief Medical Officer
After more than 10 years as a practicing hematologist and medical oncologist, Bob joined the clinical development organization at Genentech, where he served as clinical science leader for blockbuster oncology drugs Herceptin®, Tarceva® and Avastin®.
Chief Financial Officer
Tom joined our team in June 2010 with more than 35 years of experience in finance and accounting, including two decades in the life science industry. Previously, he served as Chief Financial Officer at Pacira Pharmaceuticals (Nasdaq: PCRX).
David Urso, JD
Senior Vice President, Corporate Development & General Counsel
Prior to joining us in March 2014, David co-founded Tioga Pharmaceuticals, a privately held drug development company. As a Principal at Forward Ventures, he was responsible for identifying and developing life science venture capital investments.
Karen Potts, PhD
Senior Vice President, Regulatory Affairs
Karen’s distinguished career spans both the biotechnology and pharmaceutical industries, where she has led global regulatory teams to successfully facilitate the development, approval and life cycle management of therapeutic drugs and biologics.
Richard Ghalie, MD
Senior Vice President, Clinical Development
The most recent addition to our management team, Richard is a hematologist and oncologist with more than 20 years of drug development experience. He has served as the medical lead of teams that resulted in the approval of four new indications.
Ofir Moreno, PhD
Vice President, Research & Development
An organic chemist by training, Ofir joined us in September 2010 and has played a leading role in advancing three of the company's pre-clinical drug candidates through IND-enabling studies and into clinical trials, including ME-401 and ME-344.
Pete De Spain
Vice President, Investor Relations & Corporate Communications
Pete joined the team in July 2010, soon after the company established its headquarters in the U.S. He has more than 20 years of investor relations and corporate communications experience, primarily for publicly traded biotechnology companies.
Board of Directors
Christine White, MD (Chair)Former Head of Global Medical Affairs, Biogen Idec
Charles Baltic III, JDCo-Head of Healthcare, Needham & Co.
Kevan Clemens, PhDFormer Head of Global Oncology, Roche
Nicholas Glover, PhDPresident & CEO, ProNAi Therapeutics
Daniel Gold, PhDPresident & CEO, MEI Pharma
Thomas Reynolds, MD, PhDFormer Chief Medical Officer, Seattle Genetics
William RueckertFormer Chairman, Novogen Limited